Bryce Point Capital, LLC Intellia Therapeutics, Inc. Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 26,083 shares of NTLA stock, worth $248,049. This represents 0.09% of its overall portfolio holdings.
Number of Shares
26,083Holding current value
$248,049% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding NTLA
# of Institutions
327Shares Held
91.6MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$119 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$96.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$91.3 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$48.9 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$47.1 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $723M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...